New AI technology offers a solution to the problem of drug diversion in operating rooms. The study published in the AJHP demonstrates the effectiveness of BD's software in detecting discrepancies and streamlining investigations, leading to improved patient safety.
 |
| BD's AI-powered software, HealthSightTM Diversion Management, offers a breakthrough in detecting controlled substance diversion in operating rooms, significantly improving patient safety and operational efficiency. Image: BD |
Franklin Lakes, New Jersey, USA - September 26, 2024:
Becton, Dickinson and Company (BD), a global leader in medical technology, has announced a significant breakthrough in combating the issue of drug diversion in healthcare settings. Their new artificial intelligence (AI) software, BD HealthSight Diversion Management, has proven highly effective in detecting potential instances of controlled substance misuse within operating rooms.
A recent study conducted at an Ochsner Health medical center and published in the American Journal of Health-System Pharmacy (AJHP) highlights the transformative power of this AI-driven solution. The study demonstrated that BD HealthSight can identify discrepancies and patterns in medication usage that often go unnoticed by traditional manual methods.
By analyzing data from medication storage, management, and pharmacy systems, the software can provide a comprehensive view of individual behavior and potential red flags. This is particularly valuable for large healthcare systems with multiple facilities and complex operations.
The study found a 55% increase in the identification of charting discrepancies after implementing BD HealthSight. This is due to the software's ability to track a wider range of discrepancies than manual methods, such as whole dose waste, cancelled transactions, and drugs dispensed after patient discharge.
The software also streamlined the process of investigating potential diversion incidents. The time required for auditors to review referred cases was reduced from an average of three business days to 50 minutes.
By detecting and addressing drug diversion incidents, BD HealthSight helps to protect patients from the potential harm caused by the misuse of controlled substances.
The study's findings reinforce the importance of advanced technology in addressing the issue of drug diversion, which has long been a significant challenge for healthcare organizations. By providing a more proactive and data-driven approach, BD HealthSight offers a valuable tool for safeguarding patients and maintaining the integrity of the healthcare system.